Company profile
Oragenics, Inc.
AMEX: OGEN · Healthcare · Biotechnology
#1092 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
46DFH 28DQ 74GM —SS 42
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ operating margin, net margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$9.8M
Employees
3
as of 2026-08-24
Market cap
$2.4M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$37.7k$37.7k2023
Net income-$9.8M-$9.8M2025
Operating income-$9.4M-$9.4M2025
Total assets$10.1M$10.1M2025
Liabilities$1.8M$1.8M2025
Equity$8.3M$8.3M2025
Revenue trend
FY2018 – FY2023 · USD
FY18
FY18
FY18
FY18
FY18
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2023
By product
Grant100%
By geography
Not disclosed.
The read
What is Oragenics, Inc.’s revenue?
Oragenics, Inc. booked $37.7k in FY2023 revenue, contracting 71% year over year — slower than 86% of Healthcare companies we track, at a -26140.0% net margin.
Peers · Healthcare
Neonc Technologies Holdings, Inc.10DAXIM Biotechnologies, Inc.——AREV Life Sciences Global Corp——Hi-Great Group Holding Company25DGridAI Technologies Corp.30DForte Biosciences, Inc.26DNeighbors
Hillsborough →Key facts
CEOJanet Huffman
SectorHealthcare
IndustryBiotechnology
HeadquartersTampa, FL
ExchangeAMEX: OGEN
Employees3
IPO date2004-02-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.